Pharmacogenetics in schizophrenia: A review of clozapine studies

Revista Brasileira de Psiquiatria

Volumn 35, Issue 3, 2013, Pages 305-317

  Kohlrausch, Fabiana Barzotti ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Adverse effects; Clozapine; Pharmacogenetics; Polymorphisms; Schizophrenia

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; APOLIPOPROTEIN A; ATP BINDING CASSETTE SUB FAMILY B MEMBER 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE RECEPTOR; CLOZAPINE; CYTOCHROME P450; DEBRISOQUINE; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; DYSBINDIN; GDNF FAMILY RECEPTOR ALPHA 2; MELANOCORTIN 4 RECEPTOR; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEUREXIN 1; OLANZAPINE; OXYTOCIN PREPROPEPTIDE; PEPTIDES AND PROTEINS; PROTEIN KINASE ALPHA 2 CATALYTIC SUBUNIT; PROTEIN KINASE BETA 2 NON-CATALYTIC SUBUNIT; PROTEIN KINASE GAMMA 2 NON CATALYTIC SUBUNIT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RISPERIDONE; ROUNDABOUT AXON GUIDANCE RECEPTOR HOMOLOG 1; SEROTONIN RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC ACTIVITY; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERSALIVATION; INSULIN INDUCED GENE 2; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PHARMACOGENETICS; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TONIC CLONIC SEIZURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; HUMANS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 84885112561     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2012-0970     Document Type: Review

References (171)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:e141.
2. Pádua AC, Gama CS, Lobato MI, Belmonte-de-Abreu OS. Esquizofrenia: diretrizes e algoritmo para o tratamento farmacológico. In: Cordioli AV, editor. Psicofármacos: consulta rápida. 3rd ed. Porto Alegre: Artmed; 2005. p. 343.
3. Malhotra AK. Pharmacogenomics and schizophrenia: clinical implications. Pharmacogenomics J. 2001;1:109-14.
4. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79-104.
5. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60:20-30.
6. Reynolds GP. The pharmacogenetics of symptom response to antipsychotic drugs. Psychiatry Investig. 2012;9:1-7.
7. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21:911-36.
8. Goldstein DB, Need AC, Singh R, Sisodiya SM. Potential genetic causes of heterogeneity of treatment effects. Am J Med. 2007;120:S21-5.
9. Vojvoda D, Grimmell K, Sernyak M, Mazure CM. Monozygotic twins concordant for response to clozapine. Lancet. 1996;347:61.
10. Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Gen. 2005;15:285-9.
11. Wehmeier PM, Gebhardt S, Schmidtke J, Remschmidt H, Hebebrand J, Theisen FM. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry research. 2005;133:273-6.
12. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther. 2010;35:207-11.
13. Horáeèk J, Libiger J, Höschl C, Borzova K, Hendrychová I. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract. 2001;5:71-3.
14. Anil Yagcioglu AE, Ilhan BC, Goktas MT, Babaoglu MO, Uz E, Yazici MK. Agranulocytosis related to clozapine in monozygotic twins and association with allelic variants of multidrug resistance gene MDR1. J Clin Psychopharmacology. 2011;31:247-9.
15. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25:197-220.
16. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011;25:933-69.
17. Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29:319-26.
18. Consoli G, Lastella M, Ciapparelli A, Catena Dell'Osso M, Ciofi L, Guidotti E, et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics. 2009;10:1267-76.
19. Lee ST, Ryu S, Kim SR, Kim MJ, Kim S, Kim JW, et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 2012;32:441-8.
20. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res. 2007;90:86-96.
21. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24:214-9.
22. Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol. 2007;21:718-27.
23. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry. 2003;8:109-13.
24. Malhotra AK, Buchanan RW, Kim S, Kestler L, Breier A, Pickar D, et al. Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. Schizophr Res. 1999;36:92-3.
25. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl). 2005;181:179-87.
26. Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol. 2006;16:248-59.
27. Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet. 1996;97:714-9.
28. Scharfetter J, Chaudhry HR, Hornik K, Fuchs K, Sieghart W, Kasper S, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol. 1999;10:17-20.
29. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. The Int J Neurosci. 2005;115:1539-47.
30. Hwang R, Tiwari AK, Zai CC, Felsky D, Remington E, Wallace T, et al. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:62-75.
31. Zuo L, Luo X, Krystal JH, Cramer J, Charney DS, Gelernter J. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics. 2009;19:437-46.
32. Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, MacNeil LT, Culotti JG, et al. Genetic association of the GDNF alphareceptor genes with schizophrenia and clozapine response. J Psychiatr Res. 2010;44:700-6.
33. Muller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, et al. Suggestive association between the C825T polymorphism of the Gprotein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol. 2005;15:525-31.
34. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. G-protein gene 825C. T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics. 2008;9:1429-36.
35. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995;346:281-2.
36. Yu YW, Tsai SJ, Yang KH, Lin CH, Chen MC, Hong CJ. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology. 2001;43:79-82.
37. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19:123-32.
38. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 1996;217:177-8.
39. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 1998;3:61-6.
40. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. 1995;7:169-72.
41. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia. Psychopharmacology (Berl). 2012;224:441-9.
42. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics. 2010;20:274-6.
43. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport. 1999;10:1231-3.
44. Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, et al. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophr Res. 2011;132:121-4.
45. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol. 2010;13:793-8.
46. Xu M, Xing Q, Li S, Zheng Y, Wu S, Gao R, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1026-32.
47. Arranz MJ, Bolonna AA, Munro J, Curtis CJ, Collier DA, Kerwin RW. The serotonin transporter and clozapine response. Mol Psychiatry. 2000;5:124-5.
48. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatric Res. 2010;44:1158-62.
49. Zai G, Muller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl). 2006;188:171-82.
50. Jassim G, Ferno J, Theisen FM, Haberhausen M, Christoforou A, Havik B, et al. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry. 2011;44:15-20.
51. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. Polymorphism of the adrenergic receptor alpha 2a-1291C. G genetic variation and clozapine-induced weight gain. J Neural Transm. 2005;112: 1463-8.
52. Sickert L, Muller DJ, Tiwari AK, Shaikh S, Zai C, De Souza R, et al. Association of the alpha 2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics. 2009;10:1169-76.
53. Tsai A, Liou YJ, Hong CJ, Wu CL, Tsai SJ, Bai YM. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. Neuromolecular Med. 2011;13: 328-33.
54. Hong CJ, Liou YJ, Bai YM, Chen TT, Wang YC, Tsai SJ. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010;20:359-66.
55. Muller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2012;12:156-64.
56. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogene Genomics. 2005;15:743-8.
57. Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009;29:65-8.
58. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapineinduced weight gain. Am J Psychiatry. 2003;160:677-9.
59. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2005;133B:97-100.
60. Opgen-Rhein C, Brandl EJ, Muller DJ, Neuhaus AH, Tiwari AK, Sander T, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010;11:773-80.
61. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Ferno J, Gebhardt S, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotictreated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry. 2009;14:308-17.
62. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol. 2007;27:246-51.
63. Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S, et al. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics. 2013;13:272-9.
64. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic druginduced weight gain. Arch Gen Psychiatry. 2012;69:904-12.
65. Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, Lieberman JA, Meltzer HY, et al. Association study between variants of AMPactivated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J Psychiatr Res. 2012;46:462-8.
66. Vehof J, Al Hadithy AF, Burger H, Snieder H, Risselada AJ, Wilffert B, et al. Association between the ROBO1 gene and body mass index in patients using antipsychotics. Psychiatr Genet. 2011;21:202-7.
67. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. Genetic association between TNF-alpha-308 G. A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol. 2010;25:303-9.
68. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2007;27:338-43.
69. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol. 2009;29:16-20.
70. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. The Pharmacogenomics J. 2012;12:62-7.
71. Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res. 2011;125:179-86.
72. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010;121:193-8.
73. van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, et al. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol. 2010;25:270-6.
74. Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J. 2008;8:228-36.
75. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, Jia P, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry. 2011;16:321-32.
76. Corzo D, Yunis JJ, Yunis EJ, Howard A, Lieberman JA. HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. J Clin Psychiatry. 1994;55:149-52.
77. Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapineinduced agranulocytosis in two different ethnic groups. Blood. 1995;86:3835-40.
78. Amar A, Segman RH, Shtrussberg S, Sherman L, Safirman C, Lerer B, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol. 1998;1:41-4.
79. Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A, et al. HLAB38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet. 1998;25:11-3.
80. Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics. 2001;11:135-41.
81. Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry. 2011;72:458-63.
82. Ostrousky O, Meged S, Loewenthal R, Valevski A, Weizman A, Carp H, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens. 2003;62:483-91.
83. Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1997;89:4167-74.
84. Ferrari M, Bolla E, Bortolaso P, Callegari C, Poloni N, Lecchini S, et al. Association between CYP1A2 polymorphisms and clozapineinduced adverse reactions in patients with schizophrenia. Psychiatry Res. 2012;200:1014-7.
85. Kawanishi Y, Tachikawa H, Suzuki T. Pharmacogenomics and schizophrenia. Eur J Pharmacol. 2000;410:227-41.
86. Ozaki N. Pharmacogenetics of antipsychoatics. Nagoya J Med Sci. 2004;67:1-7.
87. Human Cytochrome P450 (CYP) Allele Nomenclature Committee [Internet]. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. [cited 2013 July 1]. http://www.cypalleles. ki.se/
88. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003;13:169-72.
89. Arranz MJ, Dawson E, Shaikh S, Sham P, Sharma T, Aitchison K, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol. 1995;39:417-20.
90. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Gesteira A, Barros F, et al. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics. 2009;10:1457-66.
91. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol. 1994;37:71-4.
92. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics. 2001;1:3-10.
93. Kerwin RW, Pilowsky L, Munro J, Shaikh S, Gill M, Collier D. Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. J Clin Psychiatry. 1994;55:57-62.
94. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry. 1994;51:912-7.
95. Shaikh S, Collier DA, Sham P, Pilowsky L, Sharma T, Lin LK, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet. 1995;60:541-5.
96. Rietschel M, Naber D, Oberlander H, Holzbach R, Fimmers R, Eggermann K, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology. 1996;15:491-6.
97. Kohn Y, Ebstein RP, Heresco-Levy U, Shapira B, Nemanov L, Gritsenko I, et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol. 1997;7:39-43.
98. Kaiser R, Konneker M, Henneken M, Dettling M, Muller-Oerlinghausen B, Roots I, et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry. 2000;5:418-24.
99. Kerwin R, Owen M. Genetics of novel therapeutic targets in schizophrenia. Br J Psychiatry Suppl. 1999:1-4.
100. Gaitonde EJ, Morris A, Sivagnanasundaram S, McKenna PJ, Hunt DM, Mollon JD. Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genet. 1996;67:455-8.
101. Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry. 1998;3:72-5.
102. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, et al. Pharmacogenetic prediction of clozapine response. Lancet. 2000;355:1615-6.
103. Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl). 2002;162:18-23.
104. Barlas IO, Cetin M, Erdal ME, Semiz UB, Basoglu C, Ay ME, et al. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:56-60.
105. Hwang R, Zai C, Tiwari A, Muller DJ, Arranz MJ, Morris AG, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010;10:200-18.
106. Hwang R, Souza RP, Tiwari AK, Zai CC, Muller DJ, Potkin SG, et al. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics. 2011;12:277-91.
107. Jonsson EG, Flyckt L, Burgert E, Crocq MA, Forslund K, Mattila-Evenden M, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet. 2003;13:1-12.
108. Hwang R, Zai C, Tiwari A, Muller DJ, Arranz MJ, Morris AG, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010;10:200-18.
109. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 1992;7:261-84.
110. Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998;8:481-4.
111. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2005;15:143-51.
112. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167:763-72.
113. Szekeres G, Keri S, Juhasz A, Rimanoczy A, Szendi I, Czimmer C, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2004;124B:1-5.
114. Arranz MJ, Kerwin RW. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Ann Med. 2000;32:128-33.
115. Nimgaonkar VL, Zhang XR, Brar JS, DeLeo M, Ganguli R. 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatr Genet. 1996;6:23-7.
116. Nothen MM, Rietschel M, Erdmann J, Oberlander H, Moller HJ, Nober D, et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet. 1995;346:908-9.
117. Masellis M, Paterson AD, Badri F, Lieberman JA, Meltzer HY, Cavazzoni P, et al. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet. 1995;346:1108.
118. Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 1996;153:1092-4.
119. Lin CH, Tsai SJ, Yu YW, Song HL, Tu PC, Sim CB, et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport. 1999;10:57-60.
120. Hamdani N, Bonniere M, Ades J, Hamon M, Boni C, Gorwood P. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett. 2005;377:69-74.
121. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998;32:93-9.
122. Malhotra AK, Goldman D, Ozaki N, Rooney W, Clifton A, Buchanan RW, et al. Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport. 1996;7:2100-2.
123. Rietschel M, Naber D, Fimmers R, Moller HJ, Propping P, Nothen MM. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport. 1997;8:1999-2003.
124. Masellis M, Basile VS, Meltzer HY, Lieberman JA, Sevy S, Goldman DA, et al. Lack of association between the T--. C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res. 2001;47:49-58.
125. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport. 2000;11:2017-20.
126. Gutierrez B, Arranz MJ, Huezo-Diaz P, Dempster D, Matthiasson P, Travis M, et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res. 2002;58:93-7.
127. Tsai SJ, Hong CJ, Yu YW, Lin CH, Song HL, Lai HC, et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res. 2000;44:177-81.
128. Kaiser R, Tremblay PB, Schmider J, Henneken M, Dettling M, Muller-Oerlinghausen B, et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry. 2001;6:179-85.
129. Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett. 2000; 280:65-8.
130. Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res. 2001;49:53-8.
131. Hong CJ, Yu YW, Lin CH, Tsai SJ. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett. 2003;349:206-8.
132. Souza RP, Tampakeras M, Basile V, Shinkai T, Rosa DV, Potkin S, et al. Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human Psychopharmacol. 2009;24:676-9.
133. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet. 2001;11:219-22.
134. Mancama D, Arranz MJ, Munro J, Osborne S, Makoff A, Collier D, et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett. 2002;333:207-11.
135. Tsai SJ, Hong CJ, Yu YW, Lin CH, Liu LL. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophr Res. 2003;65:27-32.
136. Hong CJ, Lin CH, Yu YW, Yang KH, Tsai SJ. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics. 2001;11:265-8.
137. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry. 2001;62:45-66.
138. Tsai SJ, Hong CJ, Yu YW, Lin CH.-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet. 2002;360:1790.
139. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC, et al. Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet. 2004;14:139-42.
140. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a metaanalysis. Int J Neuropsychopharmacol. 2007;10:697-704.
141. Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, et al. Polymorphisms of the HTR2C gene and antipsychoticinduced weight gain: an update and meta-analysis. Pharmacogenomics. 2010;11:1561-71.
142. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a metaanalysis. Int J Neuropsychopharmacol. 2007;10:697-704.
143. Hill MJ, Reynolds GP. Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics. 2011;12:727-34.
144. Tsai SJ, Yu YW, Lin CH, Wang YC, Chen JY, Hong CJ. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology. 2004;50:37-40.
145. Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Muller DJ, Kennedy JL. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol. 2010;25:253-9.
146. Huang HH, Wang YC, Wu CL, Hong CJ, Bai YM, Tsai SJ, et al. TNF-alpha-308 G. A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neurosci Lett. 2011;504:277-80.
147. Tiwari AK, Rodgers JB, Sicard M, Zai CC, Likhodi O, Freeman N, et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1484-90.
148. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010;35:1315-24.
149. Staeker J, Leucht S, Steimer W. Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. Mol Diagn Ther. 2012;16:93-8.
150. Rietschel M, Naber D, Oberlander H, Holzbach R, Fimmers R, Eggermann K, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology. 1996;15:491-6.
151. Hong CJ, Lin CH, Yu YW, Chang SC, Wang SY, Tsai SJ. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet. 2002;12:169-71.
152. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, et al. Association between the 1291-C/G polymorphism in the adrenergic alpha-2a receptor and the metabolic syndrome. J Clin Psychopharmacol. 2010;30:667-71.
153. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol. 2004;24:613-7.
154. Dettling M, Sachse C, Muller-Oerlinghausen B, Roots I, Brockmoller J, Rolfs A, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry. 2000;33:218-20.
155. Stranger BE, Stahl EA, Raj T. Progress and promise of genomewide association studies for human complex trait genetics. Genetics. 2011;187:367-83.
156. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry. 2012;17:760-9.
157. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
158. Risch NJ. Searching for genetic determinants in the new millennium. Nature. 2000;405:847-56.
159. Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Difficulties in replication of results. Lancet. 2000;356:1359-60.
160. Flomen R, Knight J, Sham P, Kerwin R, Makoff A. Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. Nucleic Acids Res. 2004;32:2113-22.
161. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics. 2005;5:149-60.
162. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet. 1999;65:220-8.
163. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci. 2006;8:85-94.
164. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-25.
165. Jia P, Wang L, Fanous AH, Pato CN, Edwards TL, Zhao Z. Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol. 2012;8:e1002587.
166. Clarke AJ, Cooper DN. GWAS: heritability missing in action? Eur J Hum Genet. 2010;18:859-61.
167. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Ver Genet. 2009;10:392-404.
168. Risch NJ. Searching for genetic determinants in the new millennium. Nature. 2000;405:847-56.
169. Moore JH, Asselbergs FW, Williams SM. Bioinformatics challenges for genome-wide association studies. Bioinformatics. 2010;26:445-55.
170. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31.
171. Mayor S. Fitting the drug to the patient. BMJ. 2007;334:452-3.